X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DIVIS LABORATORIES - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DIVIS LABORATORIES DR. REDDYS LAB/
DIVIS LABORATORIES
 
P/E (TTM) x 29.8 29.0 102.8% View Chart
P/BV x 2.9 5.0 58.2% View Chart
Dividend Yield % 0.9 1.0 93.8%  

Financials

 DR. REDDYS LAB   DIVIS LABORATORIES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
DIVIS LABORATORIES
Mar-17
DR. REDDYS LAB/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,3971,222 278.0%   
Low Rs2,560784 326.5%   
Sales per share (Unadj.) Rs856.5153.1 559.5%  
Earnings per share (Unadj.) Rs78.039.9 195.2%  
Cash flow per share (Unadj.) Rs139.944.6 313.7%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %0.71.0 67.4%  
Book value per share (Unadj.) Rs739.8201.8 366.6%  
Shares outstanding (eoy) m165.74265.47 62.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.56.6 53.1%   
Avg P/E ratio x38.225.1 152.1%  
P/CF ratio (eoy) x21.322.5 94.6%  
Price / Book Value ratio x4.05.0 81.0%  
Dividend payout %25.725.0 102.5%   
Avg Mkt Cap Rs m493,632266,266 185.4%   
No. of employees `00022.79.7 233.0%   
Total wages/salary Rs m31,0684,687 662.8%   
Avg. sales/employee Rs Th6,259.04,175.0 149.9%   
Avg. wages/employee Rs Th1,369.8481.5 284.5%   
Avg. net profit/employee Rs Th569.71,089.3 52.3%   
INCOME DATA
Net Sales Rs m141,96140,643 349.3%  
Other income Rs m1,715749 229.0%   
Total revenues Rs m143,67641,392 347.1%   
Gross profit Rs m24,72214,460 171.0%  
Depreciation Rs m10,2661,233 832.4%   
Interest Rs m63423 2,805.3%   
Profit before tax Rs m15,53713,953 111.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9653,349 88.5%   
Profit after tax Rs m12,92110,604 121.8%  
Gross profit margin %17.435.6 48.9%  
Effective tax rate %19.124.0 79.5%   
Net profit margin %9.126.1 34.9%  
BALANCE SHEET DATA
Current assets Rs m96,83740,105 241.5%   
Current liabilities Rs m84,1996,595 1,276.8%   
Net working cap to sales %8.982.5 10.8%  
Current ratio x1.26.1 18.9%  
Inventory Days Days73119 61.9%  
Debtors Days Days9881 121.0%  
Net fixed assets Rs m102,55219,995 512.9%   
Share capital Rs m829531 156.1%   
"Free" reserves Rs m121,79253,043 229.6%   
Net worth Rs m122,62153,574 228.9%   
Long term debt Rs m5,4490-   
Total assets Rs m218,16561,585 354.2%  
Interest coverage x25.5618.4 4.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.7 98.6%   
Return on assets %6.217.3 36.0%  
Return on equity %10.519.8 53.2%  
Return on capital %12.926.1 49.4%  
Exports to sales %54.60-   
Imports to sales %9.425.2 37.0%   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,27410,259 129.4%   
Fx inflow Rs m81,67035,384 230.8%   
Fx outflow Rs m26,35510,399 253.4%   
Net fx Rs m55,31524,985 221.4%   
CASH FLOW
From Operations Rs m21,44411,493 186.6%  
From Investments Rs m-18,404-11,372 161.8%  
From Financial Activity Rs m-3,692-93 3,965.6%  
Net Cashflow Rs m-1,14428 -4,028.2%  

Share Holding

Indian Promoters % 25.5 52.0 49.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.8 45.8%  
FIIs % 35.3 19.0 185.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.2 89.0%  
Shareholders   75,885 31,796 238.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and consumer durables sector witnessing maximum buying interest.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 20, 2018 01:33 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS